<!--
title: Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2
description: DOI: 10.1038/s42003-021-02866-9
published: true
date: 2022-01-07T21:25:15.459Z
tags: #covid, #treatment, #amantadine
editor: ckeditor
dateCreated: 2022-01-07T21:25:13.049Z
-->

<p>Commun Biol</p>
<p>. 2021 Dec 1;4(1):1347.</p>
<p>doi: 10.1038/s42003-021-02866-9.</p>
<h1><strong>Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2</strong></h1>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Toft-Bertelsen+TL&amp;cauthor_id=34853399">Trine Lisberg Toft-Bertelsen</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#equal-contrib-explanation"><sup>#</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Jeppesen+MG&amp;cauthor_id=34853399">Mads Gravers Jeppesen</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#equal-contrib-explanation"><sup>#</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-3"><sup>3</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tzortzini+E&amp;cauthor_id=34853399">Eva Tzortzini</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-4"><sup>4</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Xue+K&amp;cauthor_id=34853399">Kai Xue</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-5"><sup>5</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Giller+K&amp;cauthor_id=34853399">Karin Giller</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-5"><sup>5</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Becker+S&amp;cauthor_id=34853399">Stefan Becker</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-5"><sup>5</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mujezinovic+A&amp;cauthor_id=34853399">Amer Mujezinovic</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Bentzen+BH&amp;cauthor_id=34853399">Bo Hjorth Bentzen</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=B+Andreas+L&amp;cauthor_id=34853399">Loren B Andreas</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-5"><sup>5</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kolocouris+A&amp;cauthor_id=34853399">Antonios Kolocouris</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-4"><sup>4</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kledal+TN&amp;cauthor_id=34853399">Thomas Nitschke Kledal</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-6"><sup>6</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rosenkilde+MM&amp;cauthor_id=34853399">Mette Marie Rosenkilde</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34853399/#affiliation-7"><sup>7</sup></a></p>
<p>Affiliations expand</p>
<ul>
  <li>PMID: <strong>34853399</strong></li>
  <li>PMCID: <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8636635/">PMC8636635</a></li>
  <li>DOI: <a href="https://doi.org/10.1038/s42003-021-02866-9">10.1038/s42003-021-02866-9</a></li>
</ul>
<p><strong>Free PMC article</strong></p>
<h3><strong>Erratum in</strong></h3>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/34893762/">Author Correction: Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro.</a></p>
<p>Toft-Bertelsen TL, Jeppesen MG, Tzortzini E, Xue K, Giller K, Becker S, Mujezinovic A, Bentzen BH, Andreas LB, Kolocouris A, Kledal TN, Rosenkilde MM.Commun Biol. 2021 Dec 10;4(1):1402. doi: 10.1038/s42003-021-02940-2.PMID: 34893762 <strong>Free PMC article.</strong> No abstract available.</p>
<h2><strong>Abstract</strong></h2>
<p>The dire need for COVID-19 treatments has inspired strategies of repurposing approved drugs. Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug. We demonstrate that amantadine and hexamethylene-amiloride (HMA), but not rimantadine, block the ion channel activity of Protein E from SARS-CoV-2, a conserved viroporin among coronaviruses. These findings agree with their binding to Protein E as evaluated by solution NMR and molecular dynamics simulations. Moreover, we identify two novel viroporins of SARS-CoV-2; ORF7b and ORF10, by showing ion channel activity in a X. laevis oocyte expression system. Notably, amantadine also blocks the ion channel activity of ORF10, thereby providing two ion channel targets in SARS-CoV-2 for amantadine treatment in COVID-19 patients. A screen of known viroporin inhibitors on Protein E, ORF7b, ORF10 and Protein 3a from SARS-CoV-2 revealed inhibition of Protein E and ORF7b by emodin and xanthene, the latter also blocking Protein 3a. This illustrates a general potential of well-known ion channel blockers against SARS-CoV-2 and specifically a dual molecular basis for the promising effects of amantadine in COVID-19 treatment. We therefore propose amantadine as a novel, cheap, readily available and effective way to treat COVID-19.</p>
<p>Source: https://pubmed.ncbi.nlm.nih.gov/34853399/b</p>
